National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Lesinurad (Zurampic®) for the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor.

 

Rapid Review

Commenced Completed Outcome
15/03/2017 20/03/2017 Full Pharmacoeconomic Evaluation Recommended